- Home
- RDZN vs TLSA Comparison
RDZN vs TLSA Comparison
Compare RDZN & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDZN | TLSA |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United Kingdom |
| Employees | 308 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4M | 164.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | RDZN | TLSA |
|---|---|---|
| Price | $1.71 | $1.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 618.3K | 263.9K |
| Earning Date | 02-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.77 | N/A |
| Revenue Next Year | $51.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $1.08 |
| 52 Week High | $2.56 | $2.60 |
Technical Indicators
Market Signals| Indicator | RDZN | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 41.79 |
| Support Level | $1.60 | $1.24 |
| Resistance Level | $1.99 | $1.54 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 8.82 | 23.38 |
Price Performance
Historical ComparisonAbout RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.